

Pfizer Oncology Data Presentations at the ESMO 2012 Congress

At the ESMO 2012 Congress, Pfizer Oncology will present the following data:

Lung Cancer Presentations

Crizotinib:

(Abstract #1266P) Poster Session: Retrospective Study of Clinicopathologic Factors Associated with ALK Rearrangement and Survival Outcome in Chinese Patients with NSCLC. Xu-Chao Zhang. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #1291P) Poster Session: Phase I/II Dose-Finding Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Sai-Hong Ignatius Ou. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #1267P) Poster Session: A Large Retrospective Analysis of Pemetrexed Activity in Patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Prior to Crizotinib Treatment. Giorgio V. Scagliotti. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #1268P) Poster Session: Visual Disturbances in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib. Benjamin Besse. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #1191PD) Poster Discussion Session: Clinical Activity of Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring ROS1 Gene Rearrangement. Sai-Hong Ignatius Ou. Sunday, September 30, 2012. Session Time: 12:45 – 14:15 CEST. Discussion Time: 13:15 CEST. Location: Hall B. *(Embargoed until September 17, 2012)*

(Abstract #1230PD) Poster Discussion Session: Updated Results of a Global Phase II Study with Crizotinib in Advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC). Dong-Wan Kim. Sunday, September 30, 2012. Session Time: 12:45 – 14:15 CEST. Discussion Time: 12:45 CEST. Location: Hall B. *(Embargoed until September 17, 2012)*

(Abstract #1231PD) Poster Discussion Session: Impact of Crizotinib Treatment on Patient-Reported Symptoms and Quality of Life in Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Fiona H. Blackhall. Sunday, September 30, 2012. Session Time: 12:45 – 14:15 CEST. Discussion Time: 12:45 CEST. Location: Hall B. *(Embargoed until September 17, 2012)*

(Abstract # LBA1) Presidential Symposium: Phase III Randomized Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Advanced, ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Alice Shaw. Sunday, September 30, 2012. Session Time: 16:00 – 18:00 CEST. Presentation Time: 16:00 CEST. Location: Hall A. *(Embargoed until September 30, 2012 at 16:00 CEST)*

Crizotinib/Dacomitinib:

(Abstract #1290P) Poster Session: Phase I Trial of Irreversible Pan-ERBB Inhibitor Dacomitinib in Combination with ALK/MET Inhibitor Crizotinib in Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC). Pasi A. Jänne. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

Dacomitinib:

(Abstract #12280) Proffered Papers Session: Dacomitinib (PF-00299804), an Irreversible Pan-HER Tyrosine Kinase Inhibitor (TKI), for First-Line Treatment of EGFR-Mutant or HER2-Mutant or Amplified Lung Cancers. Pasi A. Jänne. Sunday, September 30, 2012. Session Time: 9:00 – 11:00 CEST. Presentation Time: 10:15 CEST. Location: Hall E. *(Embargoed until September 17, 2012)*

Axitinib:

(Abstract #1246P) Poster Session: Randomised Phase II Study of Axitinib or Bevacizumab Combined with Paclitaxel/Carboplatin as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Chris Twelves. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

Renal Cell Carcinoma Presentations

Axitinib:

(Abstract #843P) Poster Session: Axitinib and Everolimus in the Treatment of Sunitinib-Refractory Patients with Metastatic Renal Cell Carcinoma (mRCC): Results of a Simulated Treatment Comparison Analyses. Irina Proskorovsky. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #811P) Poster Session: Clinic and Home Blood Pressure Measurements are Reliable for Guiding Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Axitinib as First-Line Therapy. Viktor Grünwald. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #1391P) Poster Session: Interpreting Overall Survival (OS) Results When Progression Free Survival (PFS) Benefits Exists in Today's Oncology Landscape – Metastatic Renal Cell Carcinoma (mRCC) Case Study. Sylvie Negrier. Sunday, September 30, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #793PD) Poster Discussion Session: Axitinib Versus Sorafenib for Advanced Renal Cell Carcinoma: Phase III Overall Survival Results and Analysis of Prognostic Factors. Robert J. Motzer. Monday, October 1, 2012. Session Time: 13:00 – 14:00 CEST. Discussion Time: 13:00 CEST. Location: Hall F2. *(Embargoed until September 17, 2012)*

Sunitinib:

(Abstract #889TiP) Poster Session: Sunitinib Treatment of Renal Adjuvant Cancer: A Randomized, Double-Blind, Phase III Study of Sunitinib Versus Placebo in Subjects at High Risk of Recurrent Renal Cell Carcinoma (RCC). Alain Ravaud. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #851P) Poster Session: A Phase IV Multicenter Study of the Efficacy and Safety of Sunitinib as First-Line Therapy in Chinese Patients with Metastatic Renal Cell Carcinoma (mRCC). Shu-Kui Qin. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #815P) Poster Session: Sunitinib Dosing Schedule and Data Collection Timepoints: Impact on Quality of Life Outcomes in Metastatic Renal Cell Carcinoma (mRCC). Andrew G. Bushmakin. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #820P) Poster Session: Sunitinib Global Expanded-Access Trial in Metastatic Renal Cell Carcinoma (mRCC) – Final Results. Martin E. Gore. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #848P) Poster Session: Overall Survival in Metastatic Renal Cell Carcinoma (mRCC): A Comparison Between Sorafenib and Best Supportive Care After First Line Treatment with Sunitinib in Sweden. Per Sandström. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #794PD) Poster Discussion Session: Novel Circulating Proteins, Single Nucleotide Polymorphisms, and Molecular Tumor Markers as Potential Biomarkers of Sunitinib Efficacy in Treatment-Naïve Patients with advanced renal cell carcinoma (RCC). Robert J. Motzer. Monday, October 1, 2012. Session Time: 13:00 – 14:00 CEST. Discussion Time: 13:00 CEST. Location: Hall F2. *(Embargoed until September 17, 2012)*

(Abstract #785O) Proffered Papers Session: Comparative Assessment of Sunitinib-Associated Adverse Events as Potential Biomarkers of Efficacy in Metastatic Renal Cell Carcinoma (mRCC). Frede Donskov. Monday, October 1, 2012. Session Time: 14:00 – 15:50 CEST. Presentation Time: 15:20 CEST. Location: Hall D. *(Embargoed until September 17, 2012)*

Temsirolimus:

(Abstract #828P) Poster Session: Evaluation of Safety, Tolerability and Activity of Temsirolimus in Patients with Advanced or Metastatic Renal Cell Carcinoma (a/mRCC) in the Usual Health Care Setting. U. Mueller. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #839P) Poster Session: Efficacy and Safety of Temsirolimus in Patients with Metastatic Renal Cell Carcinoma: Results from the Spanish Experience. L. Ruiz. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

See Below for Embargo Dates

(Abstract #LBA21_PR) Proffered Papers Session: Randomized Phase IIIb Trial of Temsirolimus and Bevacizumab Versus Interferon and Bevacizumab in Metastatic Renal Cell Carcinoma: Results from INTORACT. Brian Rini. Monday, October 1, 2012. Session Time: 14:00 – 15:50 CEST. Presentation Time: 14:00 CEST. Location: Hall D. *(Embargoed until October 1, 2012 at 14:00 CEST)*

(Abstract #LBA22_PR) Proffered Papers Session: Randomized Phase III Trial of Temsirolimus Versus Sorafenib as Second-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the INTORSECT Trial. Thomas E. Hutson. Monday, October 1, 2012. Session Time: 14:00 – 15:50 CEST. Presentation Time: 14:30 CEST. Location: Hall D. *(Embargoed until October 1, 2012 at 14:00 CEST)*

Other Presentations

Sunitinib:

(Abstract #1490P) Poster Session: Continued Sunitinib Treatment After Progressive Disease in a Worldwide Treatment-Use Trial of Patients with Gastrointestinal Stromal Tumor (GIST). Peter Reichardt. Saturday, September 29, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

(Abstract #1155O) Proffered Papers Session: Updated Overall Survival Analysis from a Phase III Study of Sunitinib Versus Placebo in Patients with Advanced Unresectable Pancreatic Neuroendocrine Tumor (NET). Sandrine Faivre. Saturday, September 29, 2012. Session Time: 14:15 – 15:45 CEST. Presentation Time: 14:30 CEST. Location: Hall K. *(Embargoed until September 17, 2012)*

Temsirolimus:

(Abstract #1107TiP) Poster Session: Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma in the Usual Health Care Setting. G. Krekeler. Sunday, September 30, 2012. Session Time: 13:00 – 14:00 CEST. Location: Hall XL. *(Embargoed until September 17, 2012)*

###